Celltrion, Inc., a Korean biopharmaceutical company, has received approval from the FDA to serve as a CMO for Bristol-Myers Squibb to produce Orencia, a treatment of rheumatoid arthritis. BMS submitted an sBLA to meet expected long-term demand for the biologic drug. “We are pleased to continue our strategic business partnership with BMS. Achieving sBLA approval from the FDA to manufacture Orencia is an important milestone that reinforces our vision to become a fully integrated global bi...